Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 8/20 | 0.35 |
| ▸ | SELP | P16109 | 3/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606633 | 0.91 | ALDH1A1 (0.38) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL2606625 | 0.86 | SELP (0.35) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL2605162 | 0.82 | SELP (0.45) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16151874 | 0.78 | GJB2 (0.36) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL10064502 | 0.77 | EPHX2 (0.39) | — | |
| SCHEMBL14478816 | 0.77 | GJB2 (0.34) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12228221 | 0.75 | SELP (0.43) | SELPKMT2A | |
| SCHEMBL2606623 | 0.75 | SELP (0.43) | SELPALDH1A1 | |
| SCHEMBL2605156 | 0.74 | SELP (0.47) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12228122 | 0.74 | SELP (0.33) | SELPSSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163705-B2 | Glycolipid and use thereof | RIKEN (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | IL4, IL2, IL5 | FBP1 1265/4885SELP 279/4885SSTR1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.